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Shining the light on physician–pharmaceutical and
medical device industry financial relationships
Lawrence Conn, JD, and Lawrence Vernaglia, JD, MPH, Boston, Mass
Long subject to legal scrutiny under the federal Anti-Kickback Statute, financial ties between physicians and drug
manufacturers have recently come under additional pressure as a result of recently enacted state and federal disclosure
laws and state gift restrictions, the latest coming in connection with the Federal Health Reform Law. These “sunshine”
laws have been motivated by the concern that gifts and payments by manufacturers to physicians may lead to conflicts of
interest and improperly influence physicians in their drug- or device-prescribing decisions. As a backdrop to these new
laws, it is helpful to review prior guidance regarding manufacturer–physician financial relationships, both from the
federal government and the industry itself. These laws do not prohibit physician involvement with industry in research
and education, but they impose various new compliance requirements on these relationships, and also in many cases,
require public disclosure of arrangements that previously were treated as confidential. It is still too early to tell if these
laws will stifle innovation, but they do require a heightened degree of diligence to avoid, at a minimum, adverse publicity
and embarrassment and, at worst, criminal and civil liability. ( J Vasc Surg 2011;54:22S-5S.)
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SVOLUNTARY GUIDANCE
Office of the Inspector General recommendations for
voluntary compliance. The federal government has, for
some time, indicated its potential concern with physician–
industry financial relationships under the Anti-Kickback Stat-
ute. The Office of the Inspector General (OIG) of the U.S.
Department of Health and Human Services stated in its 2003
Compliance ProgramGuidance for PharmaceuticalManufac-
turers:
Suppliers of health care products and services frequently
cultivate relationships with physicians in a position to gener-
ate business for them through a variety of practices, includ-
ing gifts, entertainment, and personal services compensation
arrangements. These activities have a high potential for fraud
and abuse and, historically, have generated a substantial
number of anti-kickback convictions . . . Any time a phar-
maceutical manufacturer provides anything of value to a
physician who might prescribe the manufacturer’s prod-
uct, the manufacturer should examine whether it is pro-
viding a valuable tangible benefit to the physician with the
intent to induce or reward referrals.1
In particular, the OIG focuses on potentially problem-
atic items, including entertainment, recreation, travel,
meals, or other benefits in connection with informational
or marketing presentations, as well as gifts, gratuities, and
other business courtesies. The OIG also indicated the need
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22Sor caution with educational or research grants provided to
hysicians, advising drug manufacturers to ensure that
unding is for bona fide educational or research purposes
nd in no way based on the physician’s ordering the man-
facturer’s product(s).2
The OIG also took note of the Pharmaceutical Re-
earch and Manufacturers of America’s (PhRMA) 2002
ode on Interactions with Healthcare Professionals, stating
hat although compliance with the PhRMA Code will not
rotect a manufacturer as a matter of law under the Anti-
ickback Statute, it will substantially reduce the risk of
raud and abuse and help demonstrate a good-faith effort to
omply with the applicable federal health care program
equirements.3
The PhRMA and Advanced Medical Technology
ssociation codes. The PhRMA first issued the PhRMA
ode in 2002 and later updated it in 2008 to be effective on
anuary 2009.4 The PhRmA Code is a voluntary set of
tandards and principles for the industry covering topics
uch as the provision of meals to health care professionals at
nformational presentations, financial support for con-
inuing medical education (CME) provided by the man-
facturer or a third party, consulting arrangements, and
suggested prohibition on entertainment and recre-
tional items, among other areas. The medical device
ndustry has published similar requirements, and effec-
ive as of July 1, 2009, the Advanced Medical Technol-
gy Association (AdvaMed) Board of Directors ap-
roved a matching update to its Code of Ethics on
nteractions with Health Care Professionals.
ources of enforcement authority
In addition to voluntary guidance, financial relation-
hips between physicians and manufacturers are subject to
hree primary sources of legal restrictions and enforcement.
Federal Anti-Kickback Statute. The Anti-Kickback
tatute (42 U.S.C. §1320a-7b(b)) is a criminal law that
rohibits any person from “knowingly and willfully” paying
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Volume 54, Number 18S Conn and Vernaglia 23Sor offering any remuneration in exchange for or to induce
the referral or recommendation of any item or service
covered by a federal health care program. Federal courts
have broadly interpreted the statute to prohibit any pay-
ment if one purpose of the payment is to induce the referral
of covered goods or services, irrespective of whether there
are other legitimate business purposes for the payment.
Convictions under the Anti-Kickback Statute constitute a
felony and may result in a fine not to exceed $25,000,
imprisonment up to 5 years, or both. In addition, there is
the possibility of civil exclusion from the federal health care
programs for 5 years or more and civil money penalties.
In the pharmaceutical and medical device arena, there is
a concern that physicians’ financial relationships with phar-
maceutical and medical device companies may improperly
cause them to order or prescribe those products for their
patients. If payments from such companies were made with
the intent to induce the physician to prescribe their prod-
ucts, then the Anti-Kickback Statute may be violated. It is
important to note that the recent health reform legislation
made Anti-Kickback Statute violations easier for the gov-
ernment to prove. In particular, Congress amended the
intent standard under the Anti-Kickback Statute to provide
that a person need not have actual knowledge of the statute
or specific intent for an Anti-Kickback Statute violation to
occur.5
In recognition that many common, nonabusive ar-
rangements could constitute technical violations of the law,
the OIG has promulgated regulations under the Anti-
Kickback Statute, commonly known as “safe harbors” (42
C.F.R. §1001.952). Among the activities that safe harbors
potentially cover are certain investment interests, personal
services and management contracts, discounts (also a stat-
utory exception), and warranties. Only if an arrangement
satisfies all the elements of each applicable safe harbor, then
payments under those arrangements will be protected from
criminal prosecution and civil penalties under the Anti-
Kickback Statute. Arrangements that create more than one
financial relationship may need to meet more than one safe
harbor to immunize the entire arrangement. Failure to
satisfy the applicable safe harbor(s) does not mean that an
arrangement is necessarily illegal, but rather that it may be
subject to scrutiny and prosecution.
Physicians who receive (or solicit) improper payments
and manufacturers that make (or offer) such payments are
both at risk under the Anti-Kickback Statute. Hospitals and
other participants in improper financial relationships are
similarly at risk. The federal government has increasingly
focused on investigation and prosecution in this arena,
resulting in a number of high-profile settlements. For ex-
ample, on April 27, 2010, AstraZeneca paid $520 million
to settle allegations of kickbacks to physicians in connection
with illegally marketing drugs for unapproved uses. Prior
settlements involving improper off-label marketing have
been even larger, including Pfizer paying $2.3 billion in
September 2009 and Eli Lilly settling for $1.4 billion in
January 2009. iAlthough the most attention-getting fines have been
mposed on manufacturers, physicians are also clearly in the
overnment’s prosecution cross-hairs. In the wake of the
li Lilly settlement, Lew Morris, chief counsel to the OIG,
as quoted as saying:
What we need to do is make examples of a couple of
doctors so that their colleagues see that this isn’t worth
it. . . . A common problem in illegal drug and device
marketing cases is doctors’ willingness to delude them-
selves into thinking that cash, lucrative trips, and other
kickbacks do not affect them.6
State anti-kickback laws. State anti-kickback laws,
lthough varying by individual state, tend to impose prohi-
itions similar to the federal statute. However, state laws
ypically cover referrals of business covered by any payor
or, in some cases, even if self-pay), whereas the federal
tatute applies only to items or services covered by a federal
ealth care program. In addition, state statutes may or may
ot incorporate exceptions analogous to the federal safe
arbors. For example, the Massachusetts anti-kickback stat-
te is an “all payor” statute that does not incorporate the
ederal safe harbors and has no explicit intent standard.7
any state attorneys general (including in Massachusetts)
ave signaled a willingness to interpret their laws in a way
hat is harmonious with the federal Anti-Kickback Statute,
ut there is often no guarantee of such treatment.
tate and federal sunshine laws
State laws. A number of states have adopted statutes
mposing restrictions and requirements on manufacturers
ith respect to marketing and other activities. These re-
uirements include (varying by state) items such as manda-
ory codes of conduct, “gift bans” or limitations, compli-
nce requirements, and public disclosure. For example,
innesota law prohibits giving anything of value to prac-
itioners (subject to certain exceptions),8 and California
equires manufacturers to declare annual spending limits on
ifts and promotional materials given to health care profes-
ionals.9 Numerous states require disclosure of marketing
xpenditures.10 Many also require manufacturers to adopt
odes of conduct or compliance plan requirements, or
oth.11 A state-by-state comparison of applicable require-
ents is presented in the Table.
An example of the scope of these statutes can be found
n California’s sunshine law. These provisions require phar-
aceutical companies to adopt a comprehensive compli-
nce program that is in accordance with both the OIG’s
ompliance guidance and the PhRMA Code (each dis-
ussed above) and must reflect any updates to that guid-
nce. The compliance program must explicitly establish a
pecific annual dollar limit on gifts, promotional materials,
r items or activities to a physician or other health care
rofessional in accordance with the PhRMA Code. Certain
tems (eg, drug samples, CME support, financial support
or health educational scholarships and payments for legit-
mate consulting and other professional services arrange-
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the PhRMA Code. The pharmaceutical company must
make its compliance program and an annual written decla-
ration of compliance available to the public on the pharma-
ceutical company’s Web site.
Notably, the medical societies in certain states (eg,
Massachusetts and Vermont) supported enactment of these
statutes. Still other states are considering or have recently
considered creating similar statutes, including New York,
Mississippi, New Mexico, Colorado, Illinois, Maryland,
and Texas.
State sunshine statutes implicate a number of political
“hot buttons.” The mandatory disclosure that many of
these laws entail may require manufacturers to divulge
information regarding their marketing, research, and devel-
opment initiatives that they consider to be proprietary
information or confidential trade secrets. In addition, the
mandated public disclosure of payments to physicians could
have a chilling effect on physician participation in manufac-
turer-funded research because many physicians might fear
negative reactions to their being listed as recipients of
industry dollars.
Moreover, state limitations on manufacturer expendi-
tures for items such as physician education and marketing
seminars, as well as manufacturer spending cutbacks that
may occur as a result of public disclosure requirements,
could have an adverse impact on certain sectors of a state’s
economy, such as the convention and catering industries.
Studies have shown that manufacturer payments with re-
spect to Vermont physicians, hospitals, and universities
significantly decreased in fiscal year 2008-2009 from the
previous year. This trend has been reported on the national
level as well.12
As an increasing number of states adopt such laws,
other states may be likely to follow suit and perhaps even
“compete” with respect to implementing the most strin-
gent requirements and limitations. This is particularly true
as state legislatures struggle with demonstrating a commit-
ment to contain the growth of health care expenditures.
The perception that physician prescribing practices result in
increased health care costs may well result in added pressure
to restrict payments and other expenditures that are be-
lieved to impact such practices. Given the recent federal
Table. State-by-state comparisona
State
State code of
conduct
Compliance
requirement
California X
Maine
Massachusetts X X
Minnesota
Nevada 
Vermont X X
West Virginia
aAs adapted from the Massachusetts Department of Public Health.provisions enacted as part of health reform, questions maylso arise about how state and federal requirements will
esh.
Federal physician-payment sunshine law. The Pa-
ient Protection and Affordable Care Act (PPACA) of 2010
reated the new §1128G of the Social Security Act at
6002. This provision does not ban or limit gifts or expen-
itures, but is focused instead on transparent reporting of
ransfers of value by manufacturers of drugs, devices, bio-
ogicals, and medical supplies to a physician or teaching
ospital.
The PPACA requires annual “transparency reports”
beginning March 31, 2013) to the U.S. Department of
ealth and Human Services of such payments or other
ransfers of value, subject to certain limited exceptions.
eports will be publicly available on a searchable Internet
eb site. Among the information these reports must in-
lude are the following items:
● recipient’s name;
● date of payment;
● business address, specialty, and National Provider
Identifier number;
● amount and form of the payment;
● description of the nature of the payment, including
consulting, honoraria, gift, entertainment, food,
travel, education, and research; and
● if the payment relates to marketing, education, or
research specific to a covered drug, device, biological,
or medical supply, the name of that covered item.
Delayed reporting is permitted for payments pursuant
o product research or development agreements or clinical
nvestigations. These payments must be reported on the
arlier of (1) the date of U.S. Food and Drug Administra-
ion approval or clearance, or (2) 4 years after the date of
he payment. Although these items must be reported, they
ill not be subject to public disclosure, pursuant to PPACA
r the Freedom of Information Act.
Certain payments are exempt from reporting, including
he following:
● De minimus payments ($10 for any item, $100
calendar year aggregate, both subject to a Consumer
Price Index escalator)
Disclosure
requirement
Public
disclosure
Medical
devices
X
X
X X X
X X
X
X X X
X● Educational materials that directly benefit patients
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● Items under contractual warranty
● Discounts and rebates
● In-kind items used for charity care
● Expert witness fees
● Samples (not for sale)13
PPACA §6002 also requires disclosure of physician
ownership of manufacturers and group purchasing organi-
zations other than in publicly traded companies. Such
disclosures must include the dollar amount invested, the
value of that investment, and any payments or transfers of
value to the physician. The same disclosure requirements
apply to ownership held by “immediate family members” of
physicians.14
PPACA provides for preemption, effective January 1,
2012, of state laws that require manufacturers to report the
same “type of information” regarding transfers of value as
PPACA does. No preemption exists for other types of
disclosures or entities other than the manufacturers covered
by PPACA. In addition, it also seems that state “gift bans”
(such as in Massachusetts and Vermont) enacted with the
local sunshine laws will not be preempted. Because state
laws that require disclosures beyond PPACA requirements
will remain in full force, a patchwork quilt of disclosure
requirements will remain in effect.
PPACA also provides for civil money penalties for
noncompliance with reporting requirements. If the viola-
tion is not “knowing,” penalties range from $1,000 to
$10,000 for each payment not reported (up to a maximum
of $150,000 for any one annual report). For “knowing”
failures to report, penalties range from $10,000 to
$100,000 for each unreported payment (up to a maximum
of $1 million for any one annual report).
Most of the laws addressed in this article target manu-
facturers. However, physicians still need to understand
certain key issues, including (1) whether their state prohib-
its certain types of financial relationships, (2) what informa-
tion about their business relationships will be made public,
and (3) the limits of what is permissible under the enforce-
ment authorities, including the federal and state anti-
kickback laws.
Although public disclosure may sound innocuous, the
lobbying regarding sunshine laws on the federal and state Sevels often focused on the concern that physicians’ fears of
eing listed on public Web sites would be a “Scarlet Let-
er,” causing patients to doubt that their physicians’ loyal-
ies were pure. An overreaction to this fear may result in
hysicians refusing to participate in research, education,
nd consulting. Such a reaction would result in an overall
oss to the expansion of knowledge, innovation, and edu-
ation in the pharmaceutical field. It may be too early to
now if such negative effects will occur because little per-
uasive evidence exists at this point. However, anecdotal
nd experiential evidence supports the conclusion that
hese laws are causing delays in the development of new
rrangements and relationships between physicians and
anufacturers of drugs and devices.
Transparency is the word of the day. There is a percep-
ion that more transparency will both reduce cost and
mprove quality. The impact on innovation and the ad-
ancement of research and development is far from certain.
or the foreseeable future, however, physicians and their
olleagues in industry will need to adapt to these new
equirements on both state and federal levels.
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